Sarepta Therapeutics

CRISPR corrects DMD in mice for a year in Sarepta-supported study
CRISPR corrects DMD in mice for a year in Sarepta-supported study
Fierce Biotech
Duke University
Sarepta Therapeutics
CRISPR
gene editing
DMD
Duchenne Muscular Dystrophy
Flag link:
[audio+transcript] 6 Biotech Stocks to Watch Now
[audio+transcript] 6 Biotech Stocks to Watch Now
Motley Fool
Biogen
Bluebird Bio
Global Blood Therapeutics
Aimmune Therapeutics
Vertex Pharmaceuticals
Sarepta Therapeutics
Flag link:
Moment of truth for Sarepta and Myonexus
Moment of truth for Sarepta and Myonexus
EP Vantage
Sarepta Therapeutics
gene therapy
MYO-101
Limb Girdle Muscular Dystrophy
Flag link:
3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs
3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs
Motley Fool
FDA
gene editing
Novartis
Sarepta Therapeutics
CAR-T
Alzheimer's disease
Flag link:
Hunting productivity, drugmakers pitch new 'pillars' of R&D
Hunting productivity, drugmakers pitch new 'pillars' of R&D
Biopharma Dive
R&D
Moderna Therapeutics
Sarepta Therapeutics
Ionis Pharmaceuticals
Flag link:
Six Things to Watch for at the JP Morgan Healthcare Conference
Six Things to Watch for at the JP Morgan Healthcare Conference
BioSpace
Moderna Therapeutics
Sarepta Therapeutics
Biogen
Gilead Sciences
Bluebird Bio
Flag link:
Sarepta inks deal to bolster gene therapy manufacturing
Sarepta inks deal to bolster gene therapy manufacturing
Biopharma Dive
Sarepta Therapeutics
Aldevron
gene therapy
Flag link:
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Flag link:
Sarepta, AcelRx Look to Infuse Some Cash into Their Pipelines
Sarepta, AcelRx Look to Infuse Some Cash into Their Pipelines
BioSpace
Sarepta Therapeutics
AcelRx
stock offering
Flag link:
Myonexus Therapeutics Starts Trial of First-Ever Gene Therapy for Rare Type of Muscular Dystrophy
Myonexus Therapeutics Starts Trial of First-Ever Gene Therapy for Rare Type of Muscular Dystrophy
CP Wire
Myonexus
Sarepta Therapeutics
muscular dystrophy
gene therapy
Flag link:
Myonexus Therapeutics Starts Trial of First-Ever Gene Therapy for Rare Type of Muscular Dystrophy
Myonexus
Sarepta Therapeutics
muscular dystrophy
Flag link:
Antisense startup Stoke Therapeutics secures another $90M in series B funding
Antisense startup Stoke Therapeutics secures another $90M in series B funding
Endpoints
Stoke Therapeutics
Sarepta Therapeutics
Flag link:
Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
Forbes
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
Flag link:
FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial
FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial
Endpoints
Sarepta Therapeutics
FDA
gene therapy
Duchenne Muscular Dystrophy
clinical trials
Flag link:
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Xconomy
Europe
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Flag link:
Sarepta Invests $30 Million in Gene Therapy Company
Sarepta Invests $30 Million in Gene Therapy Company
CP Wire
Lacerta Therapeutics
Sarepta Therapeutics
gene therapy
Flag link:
Sarepta Invests $30 Million in Gene Therapy Company
Lacerta Therapeutics
Sarepta Therapeutics
Flag link:
Sarepta all-in on gene therapy pipeline, adding 3 CNS treatments in $30M Lacerta deal
Sarepta all-in on gene therapy pipeline, adding 3 CNS treatments in $30M Lacerta deal
Endpoints
Sarepta Therapeutics
CNS
Pompe disease
Lacerta
Flag link:
FDA slaps a hold on Sarepta’s Duchenne MD study in the wake of stellar early results
FDA slaps a hold on Sarepta’s Duchenne MD study in the wake of stellar early results
Endpoints
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
clinical hold
gene therapy
Flag link:
3 Best Gene Therapy Stocks of 2018 (So Far)
3 Best Gene Therapy Stocks of 2018 (So Far)
Motley Fool
gene therapy
FDA
Sarepta Therapeutics
Solid Biosciences
Regnxbio
Flag link:

Pages